新たに診断された、再発または難治性の急性骨髄性白血病患者の治療におけるベネトクラクス併用化学療法
新たに診断されたまたは再発/難治性AML患者におけるFLAG-IDAによる標準的な集中AML導入/強化療法と組み合わせたBCL-2阻害剤ベネトクラクスの第1b / 2相研究
This phase Ib/II trial studies the best dose and side effects of venetoclax and how well it works when given with combination chemotherapy in treating patients with newly diagnosed acute myeloid leukemia or acute myeloid leukemia that has come back or does not respond to treatment. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine, cytarabine, filgrastim and idarubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with combination chemotherapy may work better in treating patients with acute myeloid leukemia.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVES:
I. To evaluate the safety and tolerability and to determine the dose-limiting toxicity and the maximum tolerated dose MTD of the combination of fludarabine, cytarabine, filgrastim (GCSF), idarubicin (FLAG-IDA) + venetoclax for patients with acute myeloid leukemia (AML) (Phase 1b).
II. To determine the overall activity of this combination in patients newly diagnosed or relapsed/refractory (AML) (Phase 2).
SECONDARY OBJECTIVES:
I. Determine the preliminary assessment of efficacy by response to revised International Working Group (IWG) criteria and time to response variables including overall survival (OS), event-free survival (EFS) and duration of response (DOR).
II. Determine biomarkers that may be predictive of venetoclax activity.
OUTLINE: This is a phase I, dose-escalation study of venetoclax followed by a phase II study.
INDUCTION THERAPY: Patients receive venetoclax orally (PO) on days 1-14, fludarabine intravenously (IV) over 30 minutes on days 2-6, cytarabine IV over 4 hours on days 2-6, idarubicin IV over 15-30 minutes on days 4 and 5, filgrastim subcutaneously (SC) on days 1-7, or pegfilgrastim SC after day 5. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION THERAPY: Patients receive venetoclax PO on days 1-7, fludarabine IV over 30 minutes on days 2-4, cytarabine IV over 4 hours on days 2-4, filgrastim SC on days 1-7, or pegfilgrastim SC after days 3. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may also receive idarubicin as in Induction Therapy during 1 cycle of Consolidation Therapy per the treating physician.
MAINTENANCE THERAPY: Patients receive venetoclax PO on days 1-28. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up within 30 days.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:DiNardo, MD
- 電話番号:(713) 794-1141
- メール:cdinardo@mdanderson.org
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- M D Anderson Cancer Center
-
コンタクト:
- Courtney DiNardo
- 電話番号:713-794-1141
- メール:cdinardo@mdanderson.org
-
主任研究者:
- Courtney DiNardo
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Diagnosis of AML by World Health Organization (WHO) criteria. Patients with high risk myelodysplastic syndrome (MDS) as defined by the presence of >= 10% blasts are also eligible at the discretion of the principal investigator
- Patients older than 65 who are deemed fit to receive intensive chemotherapy by the treating physician will be eligible after discussion with the principal investigator (PI).
- Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
- Creatinine clearance >= 30 mL/min based on the Cockcroft-Gault equation
- Total bilirubin < 1.5 x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement
- Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement
- Ability to understand and provide signed informed consent
- Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug
- Only patients who are relapsed, refractory, or intolerant of standard AML therapy will be eligible for Part 1 (minimum of 1 prior line of AML-directed therapy)
Exclusion Criteria:
- Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)
- Patients having received any prior BCL2 inhibitor therapy
- Subject has known active central nervous system (CNS) involvement with AML
- Patients with New York Heart Association (NYHA) class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) < 40% by echocardiogram or multi-gated acquisition (MUGA) scan
- Patients with a history of myocardial infarction within the last 6 months or unstable / uncontrolled angina pectoris or history of severe and/or uncontrolled ventricular arrhythmias
- Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
- Patients with known dysphagia, short-gut syndrome, or other conditions that would affect the ingestion or gastrointestinal absorption of drugs administered orally
- Subject has any other significant medical or psychiatric history that in the opinion of the investigator would adversely affect participation in this study
- Subject has a white blood cell count > 25 x 10{9}/L. (Note: hydroxyurea is permitted to meet this criterion)
- Nursing women, women of childbearing potential (WOCBP) with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception (a) appropriate method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment (venetoclax, FLAG-IDA)
See detailed description. |
Given IV
他の名前:
Given IV
他の名前:
Given PO
他の名前:
Given SC
他の名前:
Given IV
他の名前:
Given SC
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall response rate (ORR)
時間枠:Up to 6 years
|
Defined as complete response (CR) + CR with incomplete blood count recovery (CRi) + partial response (PR). Will be estimated along with the 95% credible interval. |
Up to 6 years
|
|
CR/CRi rate
時間枠:Up to 6 years
|
Will be estimated along with the 95% credible interval. |
Up to 6 years
|
|
Hematologic response
時間枠:Up to 6 years
|
Will be estimated along with the 95% credible interval. |
Up to 6 years
|
|
Duration of response
時間枠:From the date of initial response, assessed up to 6 years
|
Defined as the number of days from the date of initial response (PR or better) to the date of first documented disease progression/relapse or death, whichever occurs first. Will be calculated for all patients. |
From the date of initial response, assessed up to 6 years
|
|
Event-free survival
時間枠:From the date of treatment initiation, assessed up to 6 years
|
Defined as the number of days from the date of treatment initiation (i.e., course 1 day 1) to the date of documented treatment failure, relapses from CR, or death from any cause, whichever occurs first. Will be calculated for all patients. Estimated using Kaplan-Meier method. Log-rank tests will be used to compare among subgroups of patients. |
From the date of treatment initiation, assessed up to 6 years
|
|
Overall survival
時間枠:Up to 6 years
|
Estimated using Kaplan-Meier method. Log-rank tests will be used to compare among subgroups of patients. |
Up to 6 years
|
|
Anti-tumor activity
時間枠:Up to 6 years
|
Will be summarized graphically and with descriptive statistics. |
Up to 6 years
|
|
Pharmacodynamic markers
時間枠:Up to 6 years
|
Two samples t-test /Wilcoxon rank sum tests will be used to compare pharmacodynamics/pharmacokinetics (PD/PK) parameters between responder and non-responders, and logistic regression analysis will also be used to evaluate the association of PD/PK parameters with response. |
Up to 6 years
|
|
Drug exposure levels
時間枠:Up to 6 years
|
Will be summarized graphically and with descriptive statistics. |
Up to 6 years
|
|
Overall incidence and severity of all adverse events
時間枠:Up to 6 years
|
Graded using Common Toxicity Criteria version 4.0. Safety data will be summarized using frequency and percentage, by category and severity. |
Up to 6 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Morphologic leukemia-free state
時間枠:Up to 6 years
|
Will be estimated along with the 95% credible interval. |
Up to 6 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Exploratory biomarkers
時間枠:Up to 6 years
|
Will be summarized graphically and with descriptive statistics. Peripheral blood and bone marrow aspirate samples will be obtained at study specified time points. Biomarker assays may include, but are not limited to, BH3 profiling and characterization of BCL-2 and related proteins, and assessment of the depth of response and monitoring of disease recurrence by assessment of minimal residual disease (MRD) in the bone marrow. |
Up to 6 years
|
協力者と研究者
捜査官
- 主任研究者:Courtney DiNardo、M.D. Anderson Cancer Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 新生物
- 組織型別の新生物
- 血液疾患
- 白血病、骨髄性
- 白血病
- ヘミックおよびリンパ疾患
- 白血病、骨髄性、急性
- ペプチド
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 核酸、ヌクレオチド、およびヌクレオシド
- 炭化水素
- 炭化水素、周期的
- 生物学的要因
- 炭水化物
- 多環芳香族炭化水素
- 炭化水素、芳香
- 多環式化合物
- グリコシド
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- ヌクレオシド
- 細胞間シグナル伝達ペプチドとタンパク質
- アラビノヌクレオシド
- アントラサイクリン
- ナフテセン
- アミノグリコシド
- 糖タンパク質
- グリココンジュゲート
- ダウノルビシン
- コロニー刺激因子
- 造血細胞成長因子
- サイトカイン
- シタラビン
- イダルビシン
- フルダラビン
- ベネトクラックス
- 顆粒球コロニー刺激因子
- Filgrastim
- Pegfilgrastim
その他の研究ID番号
- 2016-0979
- 2016-0979 (その他の識別子:M D Anderson Cancer Center)
- NCI-2018-01119 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。